Orforglipron approved for obesity

The U.S. Food and Drug Administration approved Eli Lilly’s Foundayo, the brand name for orforglipron, on April 1 for adults with obesity or adults with overweight who also have at least one weight-related medical problem, according to the agency’s approval letter and Lilly’s announcement. The drug is taken once daily by mouth and is meant to be used with a reduced-calorie diet and increased physical activity. FDA records show Foundayo is a new molecular entity and carries a boxed warning about the risk of thyroid C-cell tumors. Lilly said the product began shipping days after the approval. ### What exactly did the FDA approve? FDA’s April 1 approval covers long-term weight reduction and weight maintenance in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition, according to the agency’s approval letter. The label identifies Foundayo as an oral glucagon-like peptide-1 receptor agonist, or GLP-1, for use alongside diet and exercise. The prescribing information says Foundayo is a tablet for oral use and lists an initial U.S. approval date of 2026. The label also includes a boxed warning on thyroid C-cell tumors and says the drug should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. ### Why is this pill drawing attention in a market dominated by injections? Lilly said Foundayo is “the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions” in its April 1 release. That administration detail sets it apart from oral semaglutide, which has fasting-related instructions, and from the injectable GLP-1 medicines that have dominated obesity treatment. Pharmacy Times reported on May 20 that the approval added a once-daily oral option to obesity care and could broaden access for patients who want to avoid injections or more complicated dosing routines. In a Pharmacy Times interview published this month, Richard Frank, chief medical officer at Vida Health, said the oral format may help address barriers tied to needle aversion, refrigeration needs and administration instructions. ### What numbers did Lilly put behind the approval? Lilly said adults taking Foundayo in the ATTAIN-1 clinical trial lost an average of 27 pounds on the highest dose. The company also said the approval was supported by data from ATTAIN-1 and ATTAIN-2, trials cited by Pharmacy Times in its coverage of the decision. The FDA’s separate April announcement on novel drug approvals said Foundayo was the first new molecular entity approved under the Commissioner’s National Priority Voucher pilot program. The agency said the decision came 50 days after filing and 294 days ahead of the application’s original PDUFA date of January 20, 2027. ### How will patients get the drug, and what will they pay? Lilly said on April 1 that Foundayo would be available through LillyDirect, with prescriptions accepted immediately and shipping beginning April 6. The company said the medicine would start at $25 per month for commercially insured patients and $149 per month for self-pay patients through that channel. An April 9 Lilly update said Foundayo had become available through LillyDirect, telehealth providers and retail pharmacies nationwide. Lilly described the rollout as broader U.S. availability following the FDA approval. ### Why are clinicians outside obesity medicine paying attention? Pharmacy Times said the approval expands the menu of obesity medicines at a time when GLP-1 therapies are becoming more common across patients with diabetes and metabolic disease. That matters for physicians in retina and cataract clinics because those practices already see large numbers of patients with diabetes, obesity and related systemic conditions. Richard Frank told Pharmacy Times that the oral option could widen use among patients who have hesitated over injections or storage requirements. For ophthalmology and other specialty clinics, that means medication histories are likely to include more oral and injectable incretin-based drugs as prescribing broadens. April 9 was Lilly’s first stated broad-availability milestone after the April 1 approval, and the FDA’s full prescribing information remains posted in the agency’s Drugs@FDA records for clinicians reviewing contraindications, warnings and dosing.